Severe congenital neutropenias

Area of Science:

• Hematology
• Genetics
• Immunology

Background:

• Severe congenital neutropenia (SCN) is a rare group of disorders marked by defective neutrophil granulocyte maturation.
• Patients experience recurrent, severe infections from infancy.
• Common genetic causes include ELANE and HAX1 mutations, impacting neutrophil elastase and G-CSF signaling.

Purpose of the Study:

• To review the pathophysiology, diagnosis, and management of severe congenital neutropenias.
• To highlight the genetic basis and potential progression to hematologic malignancies.
• To outline current treatment strategies and monitoring recommendations.

Main Methods:

• Review of existing literature on SCN pathophysiology, genetics, and clinical management.
• Analysis of diagnostic criteria including clinical, hematological, and genetic evaluations.
• Summary of therapeutic approaches, focusing on G-CSF therapy and stem cell transplantation.

Main Results:

• Identified ELANE and HAX1 as frequent mutation sites.
• Highlighted the risk of progression to myelodysplastic syndromes or acute myeloid leukemia, often involving CSF3R mutations.
• Demonstrated the efficacy of G-CSF in increasing neutrophil counts and reducing infection rates.

Conclusions:

• SCN requires comprehensive diagnosis involving genetic analysis.
• G-CSF therapy is the primary treatment, significantly improving patient outcomes.
• Long-term monitoring for disease progression and pre-leukemic mutations is essential.